EUVIMEDEUVIMED entdecken
Crossref

In vivo Pharmacokinetic/Pharmacodynamic Analysis of the Efficacy of the Cefepime/Nacubactam Combination Against β-Lactamase-Producing Enterobacterales based on the Instantaneous MIC Concept

Yuki Igarashi, Wataru Takemura, Xiaoxi Liu, Nana Kojima, Takumi Morita, Victor Tuan Giam Chuang, Yuki Enoki, Kazuaki Taguchi, Kazuaki Matsumoto

Pharmaceutical Research · 2023-10 · 40 (10) · 2423-2431

DOI: 10.1007/s11095-023-03608-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, online erschienen am 02.10.2023. Verfasst von Yuki Igarashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-Ku, Tokyo, 105-8512, Japan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Klebsiella pneumoniae. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Nacubactam (NAC) is a novel diazabicyclooctane β-lactamase inhibitor used in combination with cefepime (CFPM). In this study, we aimed to determine the target pharmacokinetics (PK) and pharmacodynamics (PD) values of CFPM/NAC in mice infected with β-lactamase-producing Enterobacterales, such as the carbapenemase-producing Enterobacterales. METHODS: Three strains of β-lactamase-producing Enterobacterales, Klebsiella pneumoniae MSC 21444, Escherichia coli MSC 20662, and K. pneumoniae ATCC BAA-1898, were used for checkerboard assays and fractionation studies and dose-range studies. A PK study was performed in neutropenic mice. Additionally, PK/PD analysis was performed based on the instantaneous minimum inhibitory concentration (MICi) concept. RESULTS: Checkerboard measurements revealed that higher NAC concentrations decreased the CFPM MIC in a concentration-dependent manner. In all tested strains, fT > MICi calculated from the PK experiments showed a high correlation with the mean change in the bacterial count of thigh-infected mice in the in vivo PD study, suggesting that fT > MICi is an optimal PK/PD parameter for monitoring the CFPM/NAC combination. The target fT > MICi values for CFPM/NAC to achieve a bacteriostatic effect, 1-log10-kill, and 2-log10-kill values were 30, 49, and 94%, respectively. CONCLUSIONS: Our results indicate that fT > MICi is a PK/PD parameter is suitable for monitoring the CFPM/NAC combination. The minimum target value for achieving a static effect against β-lactamase-producing Enterobacterales is 30%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsKlebsiella pneumoniaeAnimalsMiceCefepimebeta-LactamasesEscherichia coliMicrobial Sensitivity TestsLactamsAzabicyclo Compounds

Stichwörter der Autor:innen

antimicrobial resistancein vivo PK/PD studyinstantaneous MICnacubactamβ-lactam/β-lactamase inhibitor

Substanzen

CefepimeAnti-Bacterial Agentsbeta-LactamasesnacubactamLactamsAzabicyclo Compounds

Autor:innen und Institutionen

  • Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-Ku, Tokyo, 105-8512, Japan.
  • Discipline of Pharmacy, Curtin Medical School, Faculty of Health Sciences, Curtin University, GPO Box U1987, Perth, Western Australia, 6845, Australia.
  • Division of Pharmacodynamics, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-Ku, Tokyo, 105-8512, Japan. taguchi-kz@pha.keio.ac.jp.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Igarashi, Y., Takemura, W., Liu, X., Kojima, N., Morita, T., Chuang, V. T. G., Enoki, Y., Taguchi, K., & Matsumoto, K. (2023). In vivo Pharmacokinetic/Pharmacodynamic Analysis of the Efficacy of the Cefepime/Nacubactam Combination Against β-Lactamase-Producing Enterobacterales based on the Instantaneous MIC Concept. Pharmaceutical Research, 40(10), 2423-2431. https://doi.org/10.1007/s11095-023-03608-8

Vancouver

Igarashi Y, Takemura W, Liu X, Kojima N, Morita T, Chuang VTG, et al. In vivo Pharmacokinetic/Pharmacodynamic Analysis of the Efficacy of the Cefepime/Nacubactam Combination Against β-Lactamase-Producing Enterobacterales based on the Instantaneous MIC Concept. Pharmaceutical Research. 2023;40(10):2423-2431. doi:10.1007/s11095-023-03608-8

BibTeX
@article{Igarashi2023,
  author = {Igarashi, Yuki and Takemura, Wataru and Liu, Xiaoxi and Kojima, Nana and Morita, Takumi and Chuang, Victor Tuan Giam and Enoki, Yuki and Taguchi, Kazuaki and Matsumoto, Kazuaki},
  title = {In vivo Pharmacokinetic/Pharmacodynamic Analysis of the Efficacy of the Cefepime/Nacubactam Combination Against β-Lactamase-Producing Enterobacterales based on the Instantaneous MIC Concept},
  journal = {Pharmaceutical Research},
  year = {2023},
  volume = {40},
  number = {10},
  pages = {2423--2431},
  doi = {10.1007/s11095-023-03608-8}
}
Kostenlos starten →